Q1 Earnings Estimate for ACAD Issued By Leerink Partnrs

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical company will earn $0.04 per share for the quarter. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ Q2 2025 earnings at $0.17 EPS, Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.60 EPS, FY2027 earnings at $1.25 EPS, FY2028 earnings at $2.00 EPS and FY2029 earnings at $2.45 EPS.

Several other research firms also recently weighed in on ACAD. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. StockNews.com downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 28th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price target for the company. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

ACADIA Pharmaceuticals Stock Up 0.6 %

ACAD stock opened at $18.26 on Monday. The company has a market capitalization of $3.04 billion, a P/E ratio of 23.41 and a beta of 0.37. The company has a 50-day simple moving average of $18.44 and a 200 day simple moving average of $16.88. ACADIA Pharmaceuticals has a fifty-two week low of $14.15 and a fifty-two week high of $24.27.

Institutional Trading of ACADIA Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ACAD. SG Americas Securities LLC lifted its position in shares of ACADIA Pharmaceuticals by 380.3% in the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock worth $45,576,000 after purchasing an additional 1,966,607 shares in the last quarter. Barclays PLC lifted its position in shares of ACADIA Pharmaceuticals by 126.2% in the third quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock worth $4,269,000 after purchasing an additional 154,854 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of ACADIA Pharmaceuticals in the third quarter worth approximately $483,000. Burney Co. purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter worth approximately $6,953,000. Finally, BNP Paribas Financial Markets lifted its position in shares of ACADIA Pharmaceuticals by 259.0% in the third quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock worth $3,439,000 after purchasing an additional 161,331 shares in the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.